CN101103002A - 3,4(,5)-取代的四氢吡啶 - Google Patents

3,4(,5)-取代的四氢吡啶 Download PDF

Info

Publication number
CN101103002A
CN101103002A CNA2006800023806A CN200680002380A CN101103002A CN 101103002 A CN101103002 A CN 101103002A CN A2006800023806 A CNA2006800023806 A CN A2006800023806A CN 200680002380 A CN200680002380 A CN 200680002380A CN 101103002 A CN101103002 A CN 101103002A
Authority
CN
China
Prior art keywords
alkyl
substituted
alkoxy
unsubstituted
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800023806A
Other languages
English (en)
Chinese (zh)
Inventor
升谷敬一
入江统
二本柳
鸟谷尾淳
金轮孝则
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN101103002A publication Critical patent/CN101103002A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CNA2006800023806A 2005-01-14 2006-01-12 3,4(,5)-取代的四氢吡啶 Pending CN101103002A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0500784.4A GB0500784D0 (en) 2005-01-14 2005-01-14 Organic compounds
GB0500784.4 2005-01-14

Publications (1)

Publication Number Publication Date
CN101103002A true CN101103002A (zh) 2008-01-09

Family

ID=34224619

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800023806A Pending CN101103002A (zh) 2005-01-14 2006-01-12 3,4(,5)-取代的四氢吡啶

Country Status (12)

Country Link
US (1) US20100029647A1 (enExample)
EP (1) EP1841740A1 (enExample)
JP (1) JP2008526910A (enExample)
KR (1) KR20070094918A (enExample)
CN (1) CN101103002A (enExample)
AU (1) AU2006205877B2 (enExample)
BR (1) BRPI0606321A2 (enExample)
CA (1) CA2590898A1 (enExample)
GB (1) GB0500784D0 (enExample)
MX (1) MX2007008558A (enExample)
RU (1) RU2007130791A (enExample)
WO (1) WO2006074924A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102015682B (zh) * 2008-05-05 2014-07-16 埃科特莱茵药品有限公司 作为肾素抑制剂的3,4-取代的哌啶衍生物

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0505969D0 (en) * 2005-03-23 2005-04-27 Novartis Ag Organic compounds
GB0514203D0 (en) 2005-07-11 2005-08-17 Novartis Ag Organic compounds
US8129411B2 (en) 2005-12-30 2012-03-06 Novartis Ag Organic compounds
EP1908471A1 (en) * 2006-10-04 2008-04-09 Speedel Experimenta AG Tetrahydropyridines as renin inhibitors
US8129538B1 (en) 2007-03-28 2012-03-06 Takeda Pharmaceutical Company Limited Renin inhibitors
CA2689109A1 (en) 2007-06-25 2008-12-31 Novartis Ag N5-(2-ethoxyethyl)-n3-(2-pyridinyl) -3,5-piperidinedicarboxamide derivatives for use as renin inhibitors
US8586776B2 (en) 2009-11-05 2013-11-19 Fibrostatin, S.L. GPBP inhibition using Q2 peptidomimetics
CN103502221B (zh) 2011-03-18 2016-03-30 拜耳知识产权有限责任公司 N-(3-氨甲酰基苯基)-1h-吡唑-5-甲酰胺衍生物及其用于防治动物害虫的用途
EP2933248B1 (en) * 2012-09-14 2018-01-31 Mitsubishi Tanabe Pharma Corporation Novel renin inhibitor
WO2016114312A1 (ja) 2015-01-13 2016-07-21 日産化学工業株式会社 反応混合物中のスズ化合物の処理方法
CN110577974B (zh) * 2019-09-10 2021-07-20 杭州澳赛诺生物科技有限公司 手性3-羟基-1,2,3,6-四氢吡啶的合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE242213T1 (de) * 1995-09-07 2003-06-15 Hoffmann La Roche Neue 4-(oxyalkoxyphenyl)-3-oxy-piperidine zur behandlung von herz- und niereninsuffizienz
US6376672B1 (en) * 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
US6197959B1 (en) * 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
EP1505945B1 (en) * 2002-05-20 2008-11-05 Bristol-Myers Squibb Company Substituted cycloalkyl p1' hepatitis c virus inhibitors
CA2490138A1 (en) * 2002-06-27 2004-01-08 Actelion Pharmaceuticals Ltd. Novel tetrahydropyridine derivatives as renin inhibitors
MXPA05011478A (es) * 2003-04-29 2005-12-12 Actelion Pharmaceuticals Ltd Derivados de 1,2,3,6-tetrahidropiridina 3,4-disustituidos novedosos.
WO2005040120A1 (en) * 2003-10-09 2005-05-06 Actelion Pharmaceuticals Ltd Tetrahydropyridine derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102015682B (zh) * 2008-05-05 2014-07-16 埃科特莱茵药品有限公司 作为肾素抑制剂的3,4-取代的哌啶衍生物

Also Published As

Publication number Publication date
AU2006205877A1 (en) 2006-07-20
WO2006074924A1 (en) 2006-07-20
US20100029647A1 (en) 2010-02-04
GB0500784D0 (en) 2005-02-23
EP1841740A1 (en) 2007-10-10
AU2006205877B2 (en) 2010-01-07
WO2006074924A8 (en) 2007-04-19
KR20070094918A (ko) 2007-09-27
MX2007008558A (es) 2007-08-14
RU2007130791A (ru) 2009-02-20
BRPI0606321A2 (pt) 2009-06-16
CA2590898A1 (en) 2006-07-20
JP2008526910A (ja) 2008-07-24

Similar Documents

Publication Publication Date Title
TWI649305B (zh) 脲衍生物、或其藥理學上所容許之鹽
CN101094848A (zh) 有机化合物
JP5306821B2 (ja) レニン阻害剤としての３，５−置換ピペリジン化合物
TWI891227B (zh) 用於治療與apj受體活性相關的病狀的化合物及組成物
US20100160305A1 (en) 3, 4, 5 - Substituted Piperidine Compounds
CN101115715A (zh) 用于治疗与肾素活性有关的疾病的吡咯烷衍生物
CN101103002A (zh) 3,4(,5)-取代的四氢吡啶
US20090137566A1 (en) Substituted Piperdines as Renin Inhibitors
JP2008540357A (ja) レニン・インヒビターとしての３−モノ−および３，５−ジ置換ピペリジン誘導体
CN101326180A (zh) 哌嗪衍生物肾素抑制剂
CN119317620A (zh) 氮杂环烷基羰基环状胺化合物
CN101687847B (zh) 用作肾素抑制剂的n5-(2-乙氧基乙基)-n3-(2-吡啶基)-3，5-哌啶二甲酰胺衍生物
JP2009539905A (ja) レニンの活性に依存する疾患に有用なピロリジン誘導体
CN101365680A (zh) 作为肾素抑制剂的3,5-取代的哌啶化合物
HK40061670A (en) Compounds and compositions for treating conditions associated with apj receptor activity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20080109